Investigation of the Effect of Tumor Location in Patients with Stage III Colon Cancer Receiving Adjuvant Oxaliplatine-Based Adjuvant Chemotherapy

dc.authoridçakır, emre/0000-0003-0411-8818
dc.authoridBeypınar, İsmail/0000-0002-0853-4096
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405
dc.authorwosidçakır, emre/JVZ-2045-2024
dc.authorwosidKüçükarda, Ahmet/AGF-2120-2022
dc.authorwosidUrvay, Semiha/AAM-2335-2021
dc.authorwosidBeypınar, İsmail/AAN-1107-2020
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.contributor.authorUrvay, Semiha
dc.contributor.authorDemir, Hacer
dc.contributor.authorGokyer, Ali
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorKucukarda, Ahmet
dc.contributor.authorCakir, Emre
dc.contributor.authorBeypinar, Ismail
dc.date.accessioned2024-06-12T10:58:06Z
dc.date.available2024-06-12T10:58:06Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractLeft-sided (LCC) and right-sided (RCC) colon cancers have different prognostic and predictive features in metastatic colon cancers, however there is insufficent data about tumor location in stage III disease. The aim of this study is to investigate the effect of tumor location on prognosis in patients with stage III colon cancer. From 2006 to 2012, medical records of 215 patients who underwent primary surgery and received adjuvant oxaliplatin based chemotherapy at 5 referral centers were collected, retrospectively. Disease-free survival (DFS) and overall survival were analysed using Kaplan-Meier and log-rank tests, and prognostic facrtors were identified by Cox regression methods. Clinicopathological characteristics of patients were similar between patients with right-and left-sided colon cancers. The 3-year DFS rate was similar (88% vs 78%, p= 0.07) but the RCC was significantly associated with a shorter 3-year OS than LCC (76% vs 87%, p= 0.03). The 3-year median OS was 125.8 months for all patients groups, 92.2 (+/- 5.81) months for the RCCs and 132.2 (+/- 5.52) months for the LCCs (p= 0.037). Multivariate analysis showed that stage (HR:0.32, p= 0.042 for OS) and venous invasion (HR: 0.28, p= 0.002 for OS) were the independent prognostic factors. Although there was no DFS difference between RCCs and LCCs, poorer survival of RCC indicated that the prognosis of RCC worsened after transitioning to the metastatic stage. Tumor location may be a prognostic factor in metastatic colon cancer but not in stage III disase.en_US
dc.identifier.doi10.4999/uhod.214409
dc.identifier.endpage58en_US
dc.identifier.issn1306-133X
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85103838527en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage50en_US
dc.identifier.trdizinid1178326en_US
dc.identifier.urihttps://doi.org/10.4999/uhod.214409
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1178326
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19940
dc.identifier.volume31en_US
dc.identifier.wosWOS:000618769800007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherAkad Doktorlar Yayinevien_US
dc.relation.ispartofUhod-Uluslararasi Hematoloji-Onkoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectColon Canceren_US
dc.subjectStage IIIen_US
dc.subjectLeft-Sided Colon Cancersen_US
dc.subjectRight-Sided Colon Cancersen_US
dc.subjectMetastatic Colorectal-Canceren_US
dc.subject2 Sidesen_US
dc.subjectSurvivalen_US
dc.subjectFluorouracilen_US
dc.subjectLeucovorinen_US
dc.subjectTherapyen_US
dc.subjectEpidemiologyen_US
dc.subjectAntibodiesen_US
dc.subjectPrognosisen_US
dc.subjectOutcomesen_US
dc.titleInvestigation of the Effect of Tumor Location in Patients with Stage III Colon Cancer Receiving Adjuvant Oxaliplatine-Based Adjuvant Chemotherapyen_US
dc.typeArticleen_US

Dosyalar